- United States
- /
- Life Sciences
- /
- NasdaqGS:ICLR
Assessing ICON’s (ICLR) Valuation as Shares Recover but Remain Below Yearly Highs
Reviewed by Simply Wall St
See our latest analysis for ICON.
While ICON’s shares have slipped below their yearly highs, the 1-month share price return of 12.76% suggests that momentum could be staging a comeback. Still, long-term total shareholder return remains underwhelming, with a 1-year drop of 31.4% and only modest gains over five years.
If you’re looking to spot the market’s next movers, now is a good time to broaden your perspective and discover fast growing stocks with high insider ownership
With shares still trading at a notable discount to analyst targets and strong fundamentals in place, the question now is whether there is still value to be found in ICON or if recent gains have already captured the growth ahead.
Most Popular Narrative: 10.7% Undervalued
With ICON’s narrative fair value at $215.67 and the last close at $192.60, analysts see more upside remaining for the shares, even after their recent rebound. This most-followed narrative builds its optimism on a set of financial and strategic levers that could lift future earnings.
“Strategic investments in AI-enabled tools like iSubmit and SmartDraft are set to accelerate trials and enhance data management, which could lead to improved earnings through increased operational efficiency. ICON plans to continue significant share repurchases and evaluates M&A opportunities, underscoring their strategy to boost EPS and shareholder value.”
Curious what the blueprint is behind this bullish valuation? The forecast banks on key drivers you might not expect—from ambitious profit improvements to a bold pace of share buybacks. Dig into the numbers and you may be surprised by the scale of what’s projected.
Result: Fair Value of $215.67 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, persistent clinical trial cancellations and ongoing macroeconomic uncertainty could quickly undermine ICON’s optimistic outlook and put pressure on future revenue growth.
Find out about the key risks to this ICON narrative.
Build Your Own ICON Narrative
If you have a different take on ICON’s story or want to interpret the data for yourself, you can generate a custom outlook in just minutes with Do it your way.
A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding ICON.
Looking for more investment ideas?
Give your portfolio fresh potential by finding high-upside companies before the crowd. These unique stock picks might just uncover your next winning move.
- Tap into the market's hidden gems with these 3577 penny stocks with strong financials, featuring strong financials and growth prospects that others might overlook.
- Maximize yield by tracking these 17 dividend stocks with yields > 3%, which highlights steady income and robust dividend performance with attractive yields above 3%.
- Embrace tomorrow’s technologies now by exploring these 27 quantum computing stocks, a collection of innovators at the forefront of quantum computing breakthroughs.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqGS:ICLR
ICON
A clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally.
Undervalued with proven track record.
Similar Companies
Market Insights
Community Narratives

